Law firm Penningtons Manches Cooper has advised Oxford Endovascular, an Oxford-based medtech company spun-out from Oxford University, on its Series A funding round.
The funding round, which closed at US$10 million, was led by new investors Vulpes Investment Management and included existing investors Oxford Sciences Innovation PLC, Parkwalk Advisors and the University of Oxford with other private and institutional investors also following on.
Oxford Endovascular is working to develop a device to treat brain aneurysms. The funding will further enable them to complete development work and gain first in-human data through an early feasibility clinical study.
Penningtons Manches Cooper has advised Oxford Endovascular on a range of legal matters including its September 2020 special pandemic investment from EIT Health. Corporate senior associate Attilio Leccisotti, who has advised Oxford Endovascular since its establishment, led the team on this transaction, working with corporate partner James Went.
Gloucester Docks eatery Dr Foster is set to reopen on Friday 12 July as a…
Poole-based Greendale Construction has finished a contract to turn a dilapidated building into a luxury…
HR People Support, a Cheltenham-based provider of outsourced HR services, is celebrating its fifth anniversary.…
The positive impact of supporting startup businesses on the economy has been highlighted at an…
Greenpower Park in Coventry has called on the next UK government to accelerate domestic battery…
The planning committee at Thanet District Council has voted unanimously to give outline planning permission…